BRINGING INNOVATIVE
TREATMENTS TO PATIENTS
SUFFERING FROM
CNS DISORDERS

MARK ALTMEYER

Founder, Chief Executive Officer

Mr. Altmeyer is a Founder, Board Member and the Chief Executive Officer of Arvelle. He has 30 years of experience leading successful drug commercialization efforts as a pharmaceutical executive, with a focus on therapies for central nervous system (CNS) disorders. He was previously President and Chief Commercial Officer at Axovant.

Prior to that Mark was Chief Executive Officer and President of Otsuka America Pharmaceutical, Inc., where he led a team of 1,700 employees and helped grow the company’s revenue from $2.6 billion to over $5 billion. He led the launch of Abilify®, the top-selling CNS drug in history and the number-one selling drug in the United States in 2013. Earlier in his career, Mr. Altmeyer held a number of executive leadership roles at Bristol-Myers Squibb, including Senior Vice President, Global Commercialization, and Senior Vice President, Neuroscience Business Unit. Mr. Altmeyer received an M.B.A. from Harvard Business School and a B.A. in economics from Middlebury College.

ILISE LOMBARDO, MD

Founder, Chief Medical Officer

llise Lombardo, MD is a Founder and the Chief Medical Officer of Arvelle. Prior to that she was Chief Medical Officer at Axovant. She has 15 years of experience leading clinical development and medical affairs programs across multiple therapeutic areas including neurological and psychiatric disorders. Dr. Lombardo has successfully managed clinical development and strategy, regulatory authority approval, and post-marketing activities.

Previously, she was Vice President, Clinical Development and Medical Affairs, at FORUM Pharmaceuticals. Dr. Lombardo also previously led a multitherapeutic Medical Affairs group and development teams at Pfizer. She is a trained psychiatrist and has worked in academic research and clinical practice. Prior to entering the pharmaceutical industry, she was an Assistant Professor of Clinical Research at Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute. Dr. Lombardo received an M.D. from Yale University, an M.Phil. from the University of Cambridge, and an A.B. from Brown University.

She completed a research fellowship in molecular biology at Yale University and the University of Cambridge and completed her internship and residency in psychiatry as well as a four-year post-doctoral fellowship in molecular neuroimaging at Columbia University College of Physicians and Surgeons.

GREGORY WEINHOFF, MD

Founder, Chief Financial Officer & Business Officer

Gregory Weinhoff, MD is a Founder, Board Member and Chief Financial Officer and Chief Business Officer. He previously served as Chief Financial Officer of Axovant Sciences. He has more than 20 years of experience in healthcare finance and operations as a venture capital investor and operating executive. Previously, Dr. Weinhoff was a partner at CHL Medical Partners, where he focused on investments in start-up and early-stage companies across biotechnology, diagnostics, medical devices and healthcare services.

He was the founding Chief Executive Officer of Amicus Therapeutics and subsequently served on the company’s board of directors. He also held positions in the healthcare groups at J.H. Whitney & Co. and Morgan Stanley & Co. Dr. Weinhoff received an M.D. from Harvard Medical School, an M.B.A. from Harvard Business School (Baker Scholar), and an A.B. in economics from Harvard College.